Compare BLBD & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | INVA |
|---|---|---|
| Founded | 1927 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 2013 | 2000 |
| Metric | BLBD | INVA |
|---|---|---|
| Price | $59.17 | $20.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $68.00 | $32.80 |
| AVG Volume (30 Days) | 467.5K | ★ 575.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.78 | ★ 816.67 |
| EPS | ★ 7.33 | 1.25 |
| Revenue | ★ $1,480,099,000.00 | $217,217,000.00 |
| Revenue This Year | $5.87 | $8.95 |
| Revenue Next Year | $6.83 | $12.65 |
| P/E Ratio | ★ $8.00 | $16.83 |
| Revenue Growth | 9.87 | ★ 62.63 |
| 52 Week Low | $46.14 | $16.52 |
| 52 Week High | $83.39 | $25.15 |
| Indicator | BLBD | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 53.35 |
| Support Level | $58.09 | $20.44 |
| Resistance Level | $64.77 | $21.81 |
| Average True Range (ATR) | 1.99 | 0.42 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 15.54 | 76.89 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.